Yvonne Yaksic

Yvonne is excited and honored to attend ASH 2018. She is a Multiple Myeloma patient and advocate diagnosed in 2005. She leads the Pittsburgh Multiple Myeloma Support. Yvonne is thankful for every group member and looks forward to sharing what she learns to help empower them to be their own best advocate.

Follow Yvonne on Twitter

A Grateful ❤️

Yvonne Yaksic |

As I reflect on my first attendance at ASH, three things stand out in my mind: After seeing the presentations of the hard-working, brilliant and dedicated doctors and researchers, I know in my heart there will someday be a cure for Multiple Myeloma. I also include the brave patients, who help all Myeloma patients, by […]

I Heart Hematologists

Yvonne Yaksic |

After four days at #ASH18 as a first-time observer, I ❤️ Hematology. More importantly, I ❤️ Hematologists. If you have been following my tweets, you have seen the amazing company, I have been keeping. These brilliant and dedicated doctors are extending the lives of multiple myeloma patients along with improving the quality of our lives. […]

From a Vortex of Confusion to a Vortex of Hope

Yvonne Yaksic |

On February 14, 2005, I was diagnosed with Stage III Multiple Myeloma. My family was told to get my affairs in order. I was sent home from the hospital on thalidomide, 40mg of daily dexamethasone, and a fentanyl patch. I was caught in a vortex of confusion, pain and despair.  THEN, my daughter called the […]

Recent Blog Posts from ASH18 Team / View All
  • A Grateful ❤️

    Yvonne Yaksic |

    As I reflect on my first attendance at ASH, three things stand out in my mind: After seeing the presentations of the hard-working, brilliant and dedicated doctors and researchers, I know in my heart there will someday be a cure for Multiple Myeloma. I also include the brave patients, who help all Myeloma patients, by […]

  • #ASH18 – Coming to a Close

    Teresa Miceli |

    The American Society of Hematology (#ASH18) annual meeting is has come to an end. Monday has been traditionally known as “Myeloma Madness Monday.” This year was no different. Oral sessions included topics on the combination therapies, #CAR-T and #BiTE (Bispecific T-cell Engager) therapy. Other potential new agents in #myeloma, like venetoclax, selinexor and isatuximab, were […]

  • Twitter at #ASH18

    Cynthia Chmielewski |

    Twitter is a greatly misunderstood social media tool. When I suggest to someone to join Twitter I usually get the response, ”I don’t do Twitter.” Twitter first appeared on the social media circuits on March 21, 2006. Much of what I know about myeloma I have learned on Twitter. The use of Twitter at #ASH18 helped […]

  • BiTEs to the Fight

    Cynthia Chmielewski |

    The treatment of myeloma is rapidly changing. When I first attended the American Society of Hematology’s (ASH) Annual Meeting in 2012 Immunotherapy was still in its infancy. Although immunotherapy options were being evaluated in clinical trials, they were not available to myeloma patients in clinical practice. November, 2015 was dubbed the November to remember in […]

  • ASH 2018: Overwhelming But Enriching

    Valarie Traynham |

    ASH 2018 has come and gone, but the numerous abstracts and information presented will be built upon for many years to come. As a first time attendee to the ASH conference, I found it to be a very enriching experience. The abundance of information was overwhelming and seemed to be too much for me to […]

  • Recollections of the 60th Annual ASH Meeting and Expo

    Jim Omel |

    ASH is over but its memories are fresh. My strongest impression of the meeting is that multiple myeloma treatment advances continue to be significant at this huge yearly event. Dr. Durie explained there were an amazing 939 abstracts relating to myeloma at ASH this year. At the IMWG (International Myeloma Working Group) meeting, he said […]

  • Courage and Hope

    John DeFlice |

    Bran thought about it. “Can a man still be brave if he is afraid?” “That is the only time a man can be brave,” his father told him. — George R.R. Martin, A Game of Thrones Aside from all the ASH 18 data that I am sure that you have read about in this past […]

  • ASH 2018: My Final Thoughts, Links, and Thanks!

    Robin Tuohy |

    While this year’s ASH had 939 abstracts about multiple myeloma, I agree with Linda Huguelet that this year was a building year, and no real blockbusters. However, and it’s a big however, because there are many future blockbusters expected from the early phase 1 trials as they continue forward, I encourage that you pay attention […]

  • I’ve Got My Mind Set on a Cure!

    Michael Tuohy |

    If you have not yet noticed, I’m a fan of good music. I’ve had bands since the 70s, growing up with what’s now called classic rock. Funny how time goes by, and it’s now “classic.” I guess it’s a good thing, because I grew up in a time when music had leads and lyrics that […]

  • IMF Patient Stories and Grant Award Reception – an evening of Hope & Research!

    Robin Tuohy |

    I’d like to give special focus to the IMF’s annual Patient Stories and Brian D. Novis Research Grants Reception. Attending this reception are multiple myeloma researchers, specialists, nurses, pharma partners, patients, caregivers, and donors; all of whom are on our team of Myeloma Warriors!   This evening begins with patients sharing their stories on Living […]